Table 2.
Surface under the cumulative ranking curve (SUCRA) values for all endpoints
| SUCRA | All-cause mortality | Cardiovascular mortality | Worsening HF |
|---|---|---|---|
| Canagliflozin | 0.519 | 0.533 | 0.754 |
| Dapagliflozin | 0.437 | 0.414 | 0.537 |
| Empagliflozin | 0.684 | 0.697 | 0.677 |
| Ertugliflozin | 0.385 | 0.659 | n.a. |
| Placebo | 0.335 | 0.374 | 0.285 |
HF, heart failure; n.a., not available. SUCRA is a transformation of the mean rank that accounts both for the location and the variance of all relative treatment effects. SUCRA would be 1 when a treatment is certain to be the best and 0 when a treatment is certain to be the worst [19]